Literature DB >> 11744380

Expression of the murine msr/apj receptor and its ligand apelin is upregulated during formation of the retinal vessels.

Magali Saint-Geniez1, Bernard Masri, François Malecaze, Bernard Knibiehler, Yves Audigier.   

Abstract

We have recently identified a new G protein-coupled receptor, msr/apj, whose transcripts are detected in the endothelium of the primary blood vessels and the newly forming heart (Mech. Dev. 1999;84:199). Its expression during formation of the embryonic vasculature incited us to investigate whether expression of the receptor also increased during the formation of retinal vessels, which occurs postnatally in the mouse. Interestingly, msr/apj transcripts are indeed associated with the forming vessels and trace the centrifugal extension of the superficial vasculature. We also show that expression of the endogenous ligand apelin is upregulated at the leading edge of vessel formation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11744380     DOI: 10.1016/s0925-4773(01)00558-5

Source DB:  PubMed          Journal:  Mech Dev        ISSN: 0925-4773            Impact factor:   1.882


  24 in total

1.  Apelin modulates pathological remodeling of lymphatic endothelium after myocardial infarction.

Authors:  Florence Tatin; Edith Renaud-Gabardos; Anne-Claire Godet; Fransky Hantelys; Francoise Pujol; Florent Morfoisse; Denis Calise; Fanny Viars; Philippe Valet; Bernard Masri; Anne-Catherine Prats; Barbara Garmy-Susini
Journal:  JCI Insight       Date:  2017-06-15

Review 2.  Vascular effects of apelin: Mechanisms and therapeutic potential.

Authors:  Amreen Mughal; Stephen T O'Rourke
Journal:  Pharmacol Ther       Date:  2018-05-25       Impact factor: 12.310

3.  Ontogeny of apelin and its receptor in the rodent gastrointestinal tract.

Authors:  Guiyun Wang; Ramendra Kundu; Song Han; Xiang Qi; Ella W Englander; Thomas Quertermous; George H Greeley
Journal:  Regul Pept       Date:  2009-08-04

4.  Apelin directs endothelial cell differentiation and vascular repair following immune-mediated injury.

Authors:  Andrew G Masoud; Jiaxin Lin; Abul K Azad; Maikel A Farhan; Conrad Fischer; Lin F Zhu; Hao Zhang; Banu Sis; Zamaneh Kassiri; Ronald B Moore; Daniel Kim; Colin C Anderson; John C Vederas; Benjamin A Adam; Gavin Y Oudit; Allan G Murray
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

5.  Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis.

Authors:  Hiroyasu Kidoya; Masaya Ueno; Yoshihiro Yamada; Naoki Mochizuki; Mitsugu Nakata; Takashi Yano; Ryo Fujii; Nobuyuki Takakura
Journal:  EMBO J       Date:  2008-01-17       Impact factor: 11.598

6.  Immunohistochemical localization of apelin in human normal breast and breast carcinoma.

Authors:  Zhiqin Wang; George H Greeley; Suimin Qiu
Journal:  J Mol Histol       Date:  2007-09-06       Impact factor: 2.611

7.  Hypothalamic apelin/reactive oxygen species signaling controls hepatic glucose metabolism in the onset of diabetes.

Authors:  Anne Drougard; Thibaut Duparc; Xavier Brenachot; Lionel Carneiro; Alexandra Gouazé; Audren Fournel; Lucie Geurts; Thomas Cadoudal; Anne-Catherine Prats; Luc Pénicaud; Didier Vieau; Jean Lesage; Corinne Leloup; Alexandre Benani; Patrice D Cani; Philippe Valet; Claude Knauf
Journal:  Antioxid Redox Signal       Date:  2013-09-18       Impact factor: 8.401

8.  Apelin-APJ signaling in retinal angiogenesis.

Authors:  Yoko Kojima; Thomas Quertermous
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-10       Impact factor: 8.311

9.  Genes that distinguish physiological and pathological angiogenesis.

Authors:  Steven Seaman; Janine Stevens; Mi Young Yang; Daniel Logsdon; Cari Graff-Cherry; Brad St Croix
Journal:  Cancer Cell       Date:  2007-06       Impact factor: 31.743

10.  The analgesic effect of apelin-13 and its mechanism of action within the nitric oxide and serotonin pathways.

Authors:  M G Turtay; M Karabas; H Parlakpinar; C Colak; M Sagir
Journal:  Hippokratia       Date:  2015 Oct-Dec       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.